Bluejay Therapeutics Announces $182 Million Series C

<p><strong>SAN MATEO<&sol;strong> — Bluejay Therapeutics&comma; a leader in the development of novel therapeutics&comma; announced the successful closure of a &dollar;182 million Series C financing round&period; This capital infusion will accelerate the clinical development of BJT-778&comma; as the treatment for chronic hepatitis D &lpar;HDV&rpar;&period; The funds will also support the progression of additional promising candidates in Bluejay’s robust pipeline for the treatment for chronic hepatitis B&period; BJT-778 has received PRIME designation from EMA based on early results from the Phase 1&sol;2 study in HDV&period;<&sol;p>&NewLine;<p>This financing round was co-led by Frazier Life Sciences and a life science focused institutional investment firm&comma; with significant contributions from both new and existing investors&comma; including RA Capital Management&comma; T&period; Rowe Price&comma; Wellington Management&comma; Novo Holdings&comma; RiverVest Venture Partners&comma; Octagon Capital&comma; Arkin Bio Ventures&comma; HBM Healthcare Investments and Unicorn Capital&period;<&sol;p>&NewLine;<p>Following the completion of the Series C financing&comma; Bluejay is excited to welcome New Board Member&comma; Daniel Estes&comma; a General Partner at Frazier&comma; to its Board of Directors&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;We are immensely grateful for the robust support from both new and returning investors&comma; which reflects confidence in our strategy and our team’s ability to deliver on our mission&comma;” said Dr&period; Keting Chu&comma; Founder and CEO of Bluejay Therapeutics&period; &OpenCurlyDoubleQuote;This funding not only empowers us to drive our lead assets through critical clinical trials but also enhances our capacity to address significant unmet medical needs in global health&period;”<&sol;p>&NewLine;